-+ 0.00%
-+ 0.00%
-+ 0.00%

PURETECH FOUNDED ENTITY SEAPORT THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2A CLINICAL TRIAL EVALUATING GLYPHAGO™ IN PATIENTS WITH GENERALIZED ANXIETY DISORDER AND SLEEP DISTURBANCE

Reuters·10/07/2026 17:00:00

Please log in to view news